Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Echocardiography | 34 | 2021 | 933 | 5.540 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 15 | 2012 | 94 | 3.080 |
Why?
|
Echocardiography, Transesophageal | 14 | 2020 | 346 | 2.920 |
Why?
|
Guideline Adherence | 12 | 2020 | 226 | 2.810 |
Why?
|
Cardiology | 10 | 2021 | 113 | 2.680 |
Why?
|
Practice Guidelines as Topic | 14 | 2016 | 1034 | 1.930 |
Why?
|
Cardiovascular Diseases | 12 | 2022 | 705 | 1.810 |
Why?
|
Image Enhancement | 10 | 2012 | 567 | 1.780 |
Why?
|
Heart Diseases | 8 | 2018 | 297 | 1.690 |
Why?
|
Exercise Test | 10 | 2021 | 165 | 1.670 |
Why?
|
Image Interpretation, Computer-Assisted | 7 | 2014 | 681 | 1.470 |
Why?
|
American Heart Association | 6 | 2020 | 86 | 1.420 |
Why?
|
Ventricular Dysfunction, Left | 10 | 2007 | 327 | 1.340 |
Why?
|
Inpatients | 2 | 2021 | 308 | 1.230 |
Why?
|
Algorithms | 8 | 2014 | 1860 | 1.170 |
Why?
|
Societies, Medical | 9 | 2016 | 562 | 1.130 |
Why?
|
Cardiac Imaging Techniques | 4 | 2016 | 25 | 1.130 |
Why?
|
Magnetic Resonance Imaging | 15 | 2019 | 3433 | 1.120 |
Why?
|
Peripheral Vascular Diseases | 4 | 2009 | 61 | 1.120 |
Why?
|
Receptors, G-Protein-Coupled | 3 | 2018 | 127 | 1.110 |
Why?
|
Coronary Artery Disease | 8 | 2012 | 360 | 1.000 |
Why?
|
Electrocardiography | 5 | 2018 | 495 | 0.990 |
Why?
|
Syncope | 2 | 2021 | 34 | 0.970 |
Why?
|
Heart | 5 | 2009 | 572 | 0.960 |
Why?
|
Practice Patterns, Physicians' | 7 | 2021 | 597 | 0.960 |
Why?
|
Humans | 107 | 2022 | 88416 | 0.940 |
Why?
|
Myocardial Perfusion Imaging | 5 | 2012 | 47 | 0.900 |
Why?
|
Erectile Dysfunction | 3 | 2009 | 75 | 0.860 |
Why?
|
Myocardial Ischemia | 5 | 2008 | 161 | 0.830 |
Why?
|
Osteoarthritis, Knee | 7 | 2019 | 65 | 0.830 |
Why?
|
Pattern Recognition, Automated | 4 | 2014 | 218 | 0.800 |
Why?
|
Echocardiography, Stress | 2 | 2012 | 20 | 0.790 |
Why?
|
Magnetic Resonance Imaging, Cine | 5 | 2020 | 161 | 0.780 |
Why?
|
Brain | 4 | 2012 | 2257 | 0.750 |
Why?
|
Heart Murmurs | 1 | 2020 | 6 | 0.730 |
Why?
|
Electronic Health Records | 2 | 2021 | 340 | 0.730 |
Why?
|
Protein Multimerization | 4 | 2016 | 173 | 0.710 |
Why?
|
Appointments and Schedules | 1 | 2020 | 53 | 0.710 |
Why?
|
Advisory Committees | 3 | 2015 | 88 | 0.680 |
Why?
|
Diazomethane | 1 | 2018 | 5 | 0.660 |
Why?
|
Sensitivity and Specificity | 15 | 2012 | 2019 | 0.630 |
Why?
|
Unnecessary Procedures | 3 | 2021 | 51 | 0.630 |
Why?
|
Coronary Disease | 2 | 2010 | 261 | 0.630 |
Why?
|
Aged | 35 | 2021 | 18887 | 0.620 |
Why?
|
Quality of Health Care | 2 | 2014 | 383 | 0.620 |
Why?
|
Cardiomyopathies | 4 | 2020 | 260 | 0.600 |
Why?
|
Pandemics | 2 | 2021 | 760 | 0.590 |
Why?
|
Betacoronavirus | 1 | 2020 | 260 | 0.570 |
Why?
|
Medicare | 1 | 2020 | 420 | 0.560 |
Why?
|
Academic Medical Centers | 2 | 2009 | 383 | 0.560 |
Why?
|
Ischemic Attack, Transient | 3 | 2008 | 182 | 0.560 |
Why?
|
Preoperative Care | 3 | 2021 | 398 | 0.550 |
Why?
|
Reproducibility of Results | 15 | 2014 | 2743 | 0.540 |
Why?
|
Middle Aged | 41 | 2021 | 25626 | 0.530 |
Why?
|
Receptor, Serotonin, 5-HT2C | 1 | 2015 | 2 | 0.520 |
Why?
|
Myocardium | 3 | 2009 | 570 | 0.510 |
Why?
|
United States | 23 | 2021 | 6872 | 0.510 |
Why?
|
Heart Ventricles | 4 | 2019 | 778 | 0.500 |
Why?
|
Thoracic Surgery | 2 | 2012 | 43 | 0.500 |
Why?
|
Prevalence | 7 | 2020 | 1246 | 0.500 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 318 | 0.500 |
Why?
|
Coronavirus Infections | 1 | 2020 | 303 | 0.500 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 96 | 0.480 |
Why?
|
Fluorescence Resonance Energy Transfer | 3 | 2015 | 95 | 0.480 |
Why?
|
Knee Injuries | 4 | 2015 | 54 | 0.470 |
Why?
|
Male | 43 | 2021 | 41926 | 0.470 |
Why?
|
Nuclear Medicine | 3 | 2008 | 12 | 0.460 |
Why?
|
Coronary Circulation | 4 | 2007 | 131 | 0.460 |
Why?
|
Knee Joint | 5 | 2015 | 166 | 0.460 |
Why?
|
Cardiac Catheterization | 2 | 2012 | 298 | 0.450 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 1704 | 0.450 |
Why?
|
Stroke | 3 | 2008 | 978 | 0.430 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2003 | 42 | 0.420 |
Why?
|
Health Services Misuse | 1 | 2012 | 19 | 0.420 |
Why?
|
Health Policy | 1 | 2014 | 185 | 0.410 |
Why?
|
Female | 42 | 2021 | 45652 | 0.390 |
Why?
|
Internship and Residency | 1 | 2021 | 1036 | 0.390 |
Why?
|
Blood Pressure | 3 | 2010 | 891 | 0.370 |
Why?
|
Exercise | 2 | 2019 | 321 | 0.370 |
Why?
|
Radiopharmaceuticals | 4 | 2020 | 192 | 0.360 |
Why?
|
Prospective Studies | 9 | 2021 | 4265 | 0.350 |
Why?
|
Risk Factors | 15 | 2019 | 5434 | 0.350 |
Why?
|
Risk Assessment | 10 | 2021 | 2285 | 0.350 |
Why?
|
Diagnostic Imaging | 4 | 2016 | 476 | 0.350 |
Why?
|
Heart Rate | 2 | 2010 | 492 | 0.350 |
Why?
|
Utilization Review | 3 | 2020 | 23 | 0.350 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2011 | 113 | 0.340 |
Why?
|
Ventricular Function, Right | 1 | 2010 | 145 | 0.340 |
Why?
|
Ankle | 1 | 2009 | 20 | 0.340 |
Why?
|
Brachial Artery | 1 | 2009 | 36 | 0.340 |
Why?
|
Logistic Models | 8 | 2014 | 1204 | 0.330 |
Why?
|
Coronary Angiography | 2 | 2012 | 238 | 0.330 |
Why?
|
Blood Pressure Determination | 1 | 2009 | 60 | 0.330 |
Why?
|
HEK293 Cells | 5 | 2018 | 635 | 0.320 |
Why?
|
Internet | 1 | 2011 | 317 | 0.320 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2007 | 104 | 0.320 |
Why?
|
Embolism | 1 | 2008 | 32 | 0.320 |
Why?
|
Community Health Centers | 1 | 2009 | 115 | 0.310 |
Why?
|
Patient Selection | 2 | 2010 | 689 | 0.310 |
Why?
|
Ambulatory Care | 1 | 2009 | 186 | 0.310 |
Why?
|
Organotechnetium Compounds | 2 | 2007 | 11 | 0.310 |
Why?
|
Heart Atria | 2 | 2007 | 281 | 0.310 |
Why?
|
Pulmonary Embolism | 2 | 2008 | 228 | 0.300 |
Why?
|
Menisci, Tibial | 2 | 2019 | 25 | 0.300 |
Why?
|
Organophosphorus Compounds | 2 | 2007 | 55 | 0.300 |
Why?
|
Carotid Arteries | 1 | 2008 | 127 | 0.300 |
Why?
|
Documentation | 2 | 2021 | 103 | 0.300 |
Why?
|
Clinical Trials as Topic | 1 | 2012 | 1142 | 0.290 |
Why?
|
Thrombosis | 2 | 2007 | 301 | 0.290 |
Why?
|
Bone Marrow | 3 | 2013 | 444 | 0.290 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2006 | 8 | 0.280 |
Why?
|
Endocardium | 2 | 2004 | 98 | 0.280 |
Why?
|
Myocardial Stunning | 1 | 2006 | 12 | 0.280 |
Why?
|
Contrast Media | 5 | 2008 | 1087 | 0.280 |
Why?
|
Multivariate Analysis | 5 | 2007 | 994 | 0.280 |
Why?
|
Hospitalization | 1 | 2012 | 869 | 0.280 |
Why?
|
Arterio-Arterial Fistula | 1 | 2006 | 6 | 0.270 |
Why?
|
Myocardial Infarction | 3 | 2021 | 373 | 0.270 |
Why?
|
Adult | 19 | 2021 | 26280 | 0.260 |
Why?
|
Coronary Vessel Anomalies | 1 | 2006 | 41 | 0.260 |
Why?
|
Hypertension | 2 | 2010 | 730 | 0.260 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2012 | 1226 | 0.250 |
Why?
|
Mitral Valve Insufficiency | 3 | 2011 | 191 | 0.250 |
Why?
|
Retrospective Studies | 11 | 2021 | 8860 | 0.240 |
Why?
|
Prognosis | 7 | 2019 | 3747 | 0.240 |
Why?
|
Arteriosclerosis | 1 | 2004 | 112 | 0.240 |
Why?
|
Severity of Illness Index | 5 | 2014 | 1841 | 0.240 |
Why?
|
Mass Screening | 1 | 2009 | 631 | 0.240 |
Why?
|
Cartilage, Articular | 2 | 2015 | 68 | 0.240 |
Why?
|
Anemia, Hemolytic | 2 | 2004 | 19 | 0.240 |
Why?
|
Vascular Surgical Procedures | 1 | 2005 | 148 | 0.240 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 602 | 0.240 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2004 | 16 | 0.240 |
Why?
|
Education, Medical, Graduate | 2 | 2021 | 387 | 0.240 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 8 | 0.240 |
Why?
|
Aged, 80 and over | 10 | 2021 | 6706 | 0.240 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2004 | 27 | 0.230 |
Why?
|
Aortic Diseases | 1 | 2004 | 99 | 0.230 |
Why?
|
Thallium | 1 | 2003 | 8 | 0.230 |
Why?
|
Pulmonary Artery | 1 | 2006 | 312 | 0.230 |
Why?
|
Brain Ischemia | 1 | 2008 | 402 | 0.230 |
Why?
|
Ischemia | 1 | 2005 | 251 | 0.230 |
Why?
|
Aortic Valve Stenosis | 1 | 2005 | 143 | 0.230 |
Why?
|
Point-of-Care Systems | 2 | 2020 | 144 | 0.230 |
Why?
|
Pheochromocytoma | 1 | 2004 | 50 | 0.230 |
Why?
|
Time Factors | 8 | 2019 | 5302 | 0.220 |
Why?
|
Schools, Nursing | 1 | 2002 | 1 | 0.220 |
Why?
|
Perioperative Nursing | 1 | 2002 | 2 | 0.220 |
Why?
|
Radionuclide Imaging | 2 | 2016 | 221 | 0.220 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2004 | 82 | 0.220 |
Why?
|
Clinical Competence | 3 | 2021 | 779 | 0.220 |
Why?
|
Surveys and Questionnaires | 5 | 2019 | 2587 | 0.220 |
Why?
|
Heart Neoplasms | 2 | 2019 | 63 | 0.220 |
Why?
|
Inservice Training | 1 | 2002 | 38 | 0.220 |
Why?
|
Angina Pectoris | 1 | 2002 | 28 | 0.210 |
Why?
|
Primary Health Care | 3 | 2022 | 350 | 0.210 |
Why?
|
Cardiovascular System | 1 | 2022 | 62 | 0.210 |
Why?
|
Mitral Valve | 2 | 2004 | 260 | 0.200 |
Why?
|
Coronary Vessels | 1 | 2003 | 190 | 0.200 |
Why?
|
Age Distribution | 3 | 2010 | 200 | 0.200 |
Why?
|
Laboratories | 1 | 2021 | 44 | 0.200 |
Why?
|
Hospitals | 2 | 2021 | 298 | 0.200 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 379 | 0.200 |
Why?
|
Radiology | 2 | 2016 | 197 | 0.200 |
Why?
|
Mineralocorticoid Receptor Antagonists | 1 | 2001 | 17 | 0.190 |
Why?
|
Abdomen | 1 | 2021 | 121 | 0.190 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2001 | 38 | 0.190 |
Why?
|
Receptors, Cell Surface | 2 | 2013 | 289 | 0.190 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 90 | 0.190 |
Why?
|
Family Practice | 1 | 2001 | 85 | 0.180 |
Why?
|
Physical Examination | 2 | 2020 | 148 | 0.180 |
Why?
|
Sarcoidosis | 1 | 2020 | 72 | 0.180 |
Why?
|
Data Collection | 3 | 2011 | 374 | 0.180 |
Why?
|
Periodicals as Topic | 2 | 2012 | 168 | 0.170 |
Why?
|
Mobile Applications | 1 | 2021 | 66 | 0.170 |
Why?
|
Disease Progression | 4 | 2019 | 1489 | 0.170 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 142 | 0.170 |
Why?
|
Tachycardia, Ventricular | 1 | 2020 | 120 | 0.170 |
Why?
|
Synovitis | 1 | 2019 | 14 | 0.170 |
Why?
|
Posterior Cruciate Ligament | 1 | 2019 | 12 | 0.170 |
Why?
|
Accelerometry | 1 | 2019 | 38 | 0.170 |
Why?
|
Data Interpretation, Statistical | 2 | 2011 | 299 | 0.170 |
Why?
|
Hip Joint | 1 | 2019 | 54 | 0.170 |
Why?
|
Atropine | 2 | 2016 | 60 | 0.170 |
Why?
|
Angiography | 2 | 2012 | 208 | 0.170 |
Why?
|
Postoperative Complications | 4 | 2021 | 2280 | 0.170 |
Why?
|
Radiation Protection | 2 | 2016 | 27 | 0.170 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2021 | 101 | 0.170 |
Why?
|
Diagnostic Techniques, Cardiovascular | 2 | 2009 | 12 | 0.170 |
Why?
|
Nutrition Surveys | 1 | 2019 | 111 | 0.170 |
Why?
|
Receptors, Neurokinin-1 | 1 | 2018 | 14 | 0.170 |
Why?
|
Hospitals, University | 2 | 2010 | 195 | 0.170 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2021 | 115 | 0.160 |
Why?
|
Walking | 1 | 2019 | 89 | 0.160 |
Why?
|
Muscarinic Antagonists | 2 | 2016 | 58 | 0.160 |
Why?
|
Anterior Cruciate Ligament | 1 | 2019 | 50 | 0.160 |
Why?
|
Substance P | 1 | 2018 | 61 | 0.160 |
Why?
|
Biomarkers | 2 | 2021 | 1754 | 0.160 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 335 | 0.160 |
Why?
|
Databases, Factual | 5 | 2021 | 846 | 0.160 |
Why?
|
Chromatography, Liquid | 1 | 2018 | 105 | 0.160 |
Why?
|
Tandem Mass Spectrometry | 1 | 2018 | 104 | 0.160 |
Why?
|
Cell Membrane | 2 | 2018 | 667 | 0.160 |
Why?
|
Age Factors | 4 | 2015 | 1859 | 0.150 |
Why?
|
Curriculum | 1 | 2002 | 565 | 0.150 |
Why?
|
Receptor, Muscarinic M3 | 2 | 2015 | 12 | 0.150 |
Why?
|
Incidence | 4 | 2016 | 1588 | 0.150 |
Why?
|
Ligands | 1 | 2018 | 439 | 0.150 |
Why?
|
Stroke Volume | 3 | 2021 | 460 | 0.150 |
Why?
|
Perfusion | 2 | 2009 | 226 | 0.150 |
Why?
|
Communication | 1 | 2021 | 452 | 0.150 |
Why?
|
Heart Failure | 2 | 2011 | 1171 | 0.150 |
Why?
|
Value-Based Purchasing | 1 | 2016 | 5 | 0.140 |
Why?
|
Illinois | 3 | 2008 | 465 | 0.140 |
Why?
|
Regional Health Planning | 1 | 2016 | 13 | 0.140 |
Why?
|
Receptor, Muscarinic M1 | 1 | 2016 | 2 | 0.140 |
Why?
|
Pirenzepine | 1 | 2016 | 8 | 0.140 |
Why?
|
Trastuzumab | 1 | 2016 | 69 | 0.130 |
Why?
|
Musculoskeletal Diseases | 1 | 2016 | 34 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 5 | 2016 | 2631 | 0.130 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 1 | 2015 | 7 | 0.130 |
Why?
|
Tibial Meniscus Injuries | 1 | 2015 | 19 | 0.130 |
Why?
|
Endoscopy | 1 | 2019 | 344 | 0.130 |
Why?
|
Protein Structure, Quaternary | 1 | 2015 | 99 | 0.130 |
Why?
|
Protein Transport | 2 | 2015 | 419 | 0.130 |
Why?
|
Aftercare | 1 | 2016 | 87 | 0.120 |
Why?
|
Sex Factors | 2 | 2010 | 1062 | 0.120 |
Why?
|
Diagnosis, Differential | 4 | 2008 | 1586 | 0.120 |
Why?
|
Chicago | 2 | 2009 | 1408 | 0.120 |
Why?
|
Cohort Studies | 4 | 2021 | 2832 | 0.120 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 307 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 1 | 2014 | 105 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2014 | 160 | 0.110 |
Why?
|
Cyclopropanes | 1 | 2013 | 25 | 0.110 |
Why?
|
Robotic Surgical Procedures | 1 | 2019 | 293 | 0.110 |
Why?
|
Molecular Probe Techniques | 1 | 2013 | 9 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 565 | 0.110 |
Why?
|
Biotinylation | 1 | 2013 | 42 | 0.110 |
Why?
|
Butyrates | 1 | 2013 | 46 | 0.110 |
Why?
|
Arthralgia | 1 | 2013 | 38 | 0.110 |
Why?
|
Thiazoles | 1 | 2013 | 128 | 0.110 |
Why?
|
Receptors, Neuropeptide | 1 | 2012 | 7 | 0.100 |
Why?
|
Microspheres | 2 | 2002 | 108 | 0.100 |
Why?
|
Calibration | 1 | 2012 | 102 | 0.100 |
Why?
|
Medical Oncology | 1 | 2016 | 375 | 0.100 |
Why?
|
Acute Disease | 3 | 2015 | 838 | 0.100 |
Why?
|
Neuropeptides | 1 | 2012 | 113 | 0.100 |
Why?
|
Bone Density | 1 | 2013 | 209 | 0.100 |
Why?
|
Models, Cardiovascular | 1 | 2012 | 104 | 0.100 |
Why?
|
Acetamides | 1 | 2011 | 26 | 0.100 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 427 | 0.100 |
Why?
|
Follow-Up Studies | 4 | 2016 | 3652 | 0.100 |
Why?
|
MAP Kinase Signaling System | 1 | 2012 | 197 | 0.100 |
Why?
|
Evidence-Based Practice | 1 | 2011 | 45 | 0.100 |
Why?
|
Diagnostic Test Approval | 1 | 2010 | 2 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2014 | 771 | 0.090 |
Why?
|
General Practitioners | 1 | 2010 | 11 | 0.090 |
Why?
|
Forecasting | 2 | 2019 | 305 | 0.090 |
Why?
|
Fractures, Bone | 1 | 2012 | 123 | 0.090 |
Why?
|
Quality Improvement | 1 | 2014 | 440 | 0.090 |
Why?
|
Fatty Acids | 1 | 2011 | 131 | 0.090 |
Why?
|
Quality Control | 1 | 2010 | 116 | 0.090 |
Why?
|
Physical Exertion | 1 | 2010 | 38 | 0.090 |
Why?
|
Sample Size | 1 | 2010 | 129 | 0.090 |
Why?
|
Radiography | 4 | 2014 | 806 | 0.090 |
Why?
|
Health Care Costs | 1 | 2012 | 233 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2012 | 385 | 0.090 |
Why?
|
Phantoms, Imaging | 1 | 2012 | 450 | 0.090 |
Why?
|
Prone Position | 1 | 2009 | 56 | 0.080 |
Why?
|
Reference Values | 1 | 2010 | 665 | 0.080 |
Why?
|
Canada | 2 | 2022 | 205 | 0.080 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2008 | 50 | 0.080 |
Why?
|
Mutagenesis, Site-Directed | 3 | 2015 | 283 | 0.080 |
Why?
|
Recovery of Function | 1 | 2010 | 290 | 0.080 |
Why?
|
Microbubbles | 1 | 2008 | 36 | 0.080 |
Why?
|
Peptides | 1 | 2012 | 646 | 0.080 |
Why?
|
Gene Expression | 1 | 2013 | 1311 | 0.080 |
Why?
|
Observer Variation | 2 | 2014 | 607 | 0.080 |
Why?
|
Tomography, Spiral Computed | 1 | 2008 | 76 | 0.080 |
Why?
|
Embolectomy | 1 | 2007 | 6 | 0.080 |
Why?
|
Hypertension, Pulmonary | 1 | 2011 | 351 | 0.070 |
Why?
|
Odds Ratio | 1 | 2009 | 685 | 0.070 |
Why?
|
Gadolinium DTPA | 1 | 2008 | 264 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2016 | 8139 | 0.070 |
Why?
|
Single-Blind Method | 1 | 2006 | 150 | 0.070 |
Why?
|
False Positive Reactions | 1 | 2006 | 222 | 0.070 |
Why?
|
ROC Curve | 1 | 2008 | 773 | 0.070 |
Why?
|
Intermittent Claudication | 1 | 2005 | 20 | 0.070 |
Why?
|
Internal Mammary-Coronary Artery Anastomosis | 1 | 2005 | 9 | 0.070 |
Why?
|
Esophageal Perforation | 1 | 2005 | 18 | 0.070 |
Why?
|
Risk | 1 | 2007 | 660 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 525 | 0.070 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2005 | 64 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2008 | 341 | 0.060 |
Why?
|
Statistics as Topic | 1 | 2006 | 235 | 0.060 |
Why?
|
Aneurysm | 1 | 2005 | 60 | 0.060 |
Why?
|
Comorbidity | 2 | 2006 | 946 | 0.060 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 224 | 0.060 |
Why?
|
Survival Analysis | 2 | 2005 | 1542 | 0.060 |
Why?
|
Probability | 1 | 2006 | 356 | 0.060 |
Why?
|
Radiation Dosage | 2 | 2016 | 226 | 0.060 |
Why?
|
Cerebrovascular Disorders | 1 | 2005 | 143 | 0.060 |
Why?
|
Gallstones | 1 | 2004 | 15 | 0.060 |
Why?
|
Vascular Diseases | 1 | 2005 | 117 | 0.060 |
Why?
|
Creatine Kinase, MB Form | 1 | 2004 | 7 | 0.060 |
Why?
|
Extremities | 1 | 2005 | 167 | 0.060 |
Why?
|
Regression Analysis | 1 | 2005 | 594 | 0.060 |
Why?
|
Creatine Kinase | 1 | 2004 | 52 | 0.060 |
Why?
|
Aorta | 1 | 2005 | 286 | 0.060 |
Why?
|
Myxoma | 1 | 2004 | 30 | 0.060 |
Why?
|
Myocardial Reperfusion | 1 | 2004 | 28 | 0.060 |
Why?
|
Injections, Intravenous | 1 | 2004 | 241 | 0.060 |
Why?
|
Heart Valve Prosthesis | 1 | 2004 | 97 | 0.060 |
Why?
|
Smoking | 1 | 2007 | 617 | 0.060 |
Why?
|
Rest | 1 | 2003 | 49 | 0.060 |
Why?
|
Diabetes Mellitus | 2 | 2007 | 743 | 0.060 |
Why?
|
Pulmonary Veins | 1 | 2004 | 88 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2005 | 858 | 0.060 |
Why?
|
Glucuronosyltransferase | 1 | 2004 | 185 | 0.060 |
Why?
|
Isoenzymes | 1 | 2004 | 272 | 0.060 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2004 | 107 | 0.060 |
Why?
|
Blood Flow Velocity | 1 | 2003 | 199 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2019 | 1044 | 0.050 |
Why?
|
California | 1 | 2002 | 143 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2005 | 255 | 0.050 |
Why?
|
Education, Medical, Undergraduate | 1 | 2005 | 178 | 0.050 |
Why?
|
Microcirculation | 1 | 2002 | 106 | 0.050 |
Why?
|
Anemia, Sickle Cell | 1 | 2004 | 143 | 0.050 |
Why?
|
Allosteric Regulation | 2 | 2013 | 68 | 0.050 |
Why?
|
Primary Prevention | 1 | 2022 | 79 | 0.050 |
Why?
|
Length of Stay | 1 | 2005 | 726 | 0.050 |
Why?
|
Graft Occlusion, Vascular | 1 | 2002 | 99 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2016 | 2974 | 0.050 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2002 | 69 | 0.050 |
Why?
|
Fluorocarbons | 1 | 2002 | 72 | 0.050 |
Why?
|
Albumins | 1 | 2002 | 130 | 0.050 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2002 | 93 | 0.050 |
Why?
|
Amino Acid Substitution | 2 | 2013 | 338 | 0.050 |
Why?
|
Survival Rate | 1 | 2005 | 1881 | 0.050 |
Why?
|
Arginine Vasopressin | 1 | 2001 | 44 | 0.050 |
Why?
|
Venous Thrombosis | 1 | 2004 | 250 | 0.050 |
Why?
|
Atrial Natriuretic Factor | 1 | 2001 | 39 | 0.050 |
Why?
|
Neoplasms | 1 | 2016 | 2999 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2004 | 389 | 0.050 |
Why?
|
Renin-Angiotensin System | 1 | 2001 | 80 | 0.050 |
Why?
|
Mitral Valve Prolapse | 1 | 2000 | 24 | 0.040 |
Why?
|
Models, Molecular | 2 | 2015 | 1295 | 0.040 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2004 | 516 | 0.040 |
Why?
|
Adolescent | 3 | 2021 | 9135 | 0.040 |
Why?
|
Genetic Variation | 1 | 2004 | 1368 | 0.040 |
Why?
|
Heart Arrest | 1 | 2021 | 268 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2002 | 1848 | 0.040 |
Why?
|
Hemodynamics | 1 | 2001 | 727 | 0.040 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 956 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2004 | 1093 | 0.040 |
Why?
|
Animals | 2 | 2013 | 27171 | 0.030 |
Why?
|
Pregnancy | 1 | 2004 | 2990 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2016 | 121 | 0.030 |
Why?
|
Drug Inverse Agonism | 1 | 2015 | 3 | 0.030 |
Why?
|
Scopolamine Derivatives | 1 | 2015 | 4 | 0.030 |
Why?
|
Tiotropium Bromide | 1 | 2015 | 4 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2015 | 85 | 0.030 |
Why?
|
Radioligand Assay | 1 | 2015 | 32 | 0.030 |
Why?
|
Muscarinic Agonists | 1 | 2015 | 23 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2015 | 129 | 0.030 |
Why?
|
Glycosylation | 1 | 2015 | 129 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2015 | 112 | 0.030 |
Why?
|
Computer Systems | 1 | 2014 | 79 | 0.030 |
Why?
|
Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2013 | 11 | 0.030 |
Why?
|
Enteroendocrine Cells | 1 | 2013 | 7 | 0.030 |
Why?
|
Benzeneacetamides | 1 | 2013 | 11 | 0.030 |
Why?
|
Lipolysis | 1 | 2013 | 23 | 0.030 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2013 | 45 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2013 | 116 | 0.030 |
Why?
|
Cholesterol | 1 | 2015 | 354 | 0.030 |
Why?
|
Tibia | 1 | 2013 | 77 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2013 | 100 | 0.030 |
Why?
|
Orexin Receptors | 1 | 2012 | 1 | 0.030 |
Why?
|
Orexins | 1 | 2012 | 8 | 0.030 |
Why?
|
Fourier Analysis | 1 | 2012 | 126 | 0.030 |
Why?
|
Larynx | 1 | 2012 | 38 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 71 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 77 | 0.030 |
Why?
|
Adipocytes | 1 | 2013 | 163 | 0.030 |
Why?
|
Linear Models | 1 | 2013 | 423 | 0.020 |
Why?
|
Cell Line | 1 | 2016 | 2498 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2004 | 2332 | 0.020 |
Why?
|
Pain Measurement | 1 | 2013 | 329 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2015 | 510 | 0.020 |
Why?
|
Biosensing Techniques | 1 | 2012 | 73 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 741 | 0.020 |
Why?
|
Body Mass Index | 1 | 2014 | 767 | 0.020 |
Why?
|
Protein Structure, Secondary | 1 | 2012 | 331 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2012 | 276 | 0.020 |
Why?
|
Systole | 1 | 2010 | 114 | 0.020 |
Why?
|
Binding Sites | 1 | 2013 | 1113 | 0.020 |
Why?
|
Awareness | 1 | 2010 | 89 | 0.020 |
Why?
|
Child | 2 | 2015 | 7079 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 453 | 0.020 |
Why?
|
Phosphorylation | 1 | 2012 | 1129 | 0.020 |
Why?
|
Kinetics | 1 | 2012 | 1528 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1484 | 0.020 |
Why?
|
Young Adult | 1 | 2021 | 6189 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 244 | 0.020 |
Why?
|
Computer Simulation | 1 | 2012 | 1095 | 0.020 |
Why?
|
Vasodilator Agents | 1 | 2008 | 146 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2010 | 356 | 0.020 |
Why?
|
Rats | 1 | 2013 | 4032 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2011 | 2873 | 0.020 |
Why?
|
Body Surface Area | 1 | 2005 | 36 | 0.020 |
Why?
|
Midwestern United States | 1 | 2005 | 82 | 0.020 |
Why?
|
Shock | 1 | 2005 | 44 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 307 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 2404 | 0.020 |
Why?
|
Heart Valve Diseases | 1 | 2005 | 115 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2004 | 114 | 0.010 |
Why?
|
Age of Onset | 1 | 2004 | 311 | 0.010 |
Why?
|
Equipment Design | 1 | 2005 | 415 | 0.010 |
Why?
|
DNA Primers | 1 | 2004 | 543 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 2005 | 234 | 0.010 |
Why?
|
Educational Measurement | 1 | 2005 | 230 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2005 | 381 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 902 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2004 | 203 | 0.010 |
Why?
|
Anticoagulants | 1 | 2004 | 423 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 2331 | 0.010 |
Why?
|
Aging | 1 | 2004 | 710 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 1867 | 0.010 |
Why?
|
Students, Medical | 1 | 2005 | 418 | 0.010 |
Why?
|
Mice | 1 | 2013 | 11696 | 0.010 |
Why?
|
DNA | 1 | 2004 | 1308 | 0.010 |
Why?
|